HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2022 January 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2021 July ; 30(7): 1387–1396. doi:10.1158/1055-9965.EPI-20-1528.

Cancer Mortality Disparities among Asian American and Native Hawaiian/Pacific Islander Populations in California

Heidy N. Medina[1], **Karen E. Callahan**[2], **Cyllene R. Morris**[3], **Caroline A. Thompson**[4], **Adugna Siweya**[2], **Paulo S. Pinheiro**[1,5]

[1]Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL

[2]School of Public Health, University of Nevada, Las Vegas, Nevada

[3]California Cancer Reporting and Epidemiologic Surveillance Program, UC Davis Comprehensive Cancer Center/ UC Davis Health, Davis, California

[4]School of Public Health, San Diego State University, Sutter Health Palo Alto Medical Foundation Research Institute, University of California San Diego School of Medicine, San Diego, California

[5]Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

Abstract

Background: Asian American and Native Hawaiian/Pacific Islanders (AANHPI) are the fastest growing minority in the US. Cancer is the leading cause of death for AANHPIs, despite relatively lower cancer morbidity and mortality. Their recent demographic growth facilitates a detailed identification of AANHPI populations with higher cancer risk.

Methods: Age-adjusted, sex-stratified, site-specific cancer mortality rates from California for 2012–2017 were computed for AANHPI groups: Chinese, Filipino, South Asian, Vietnamese, Korean, Japanese, Southeast Asian (i.e., Cambodian, Hmong, Laotian, Thai), and Native Hawaiian and Other Pacific Islander (NHOPI). Regression-derived mortality rate ratios (MRR) were used to compare each AANHPI group to non-Hispanic whites (NHWs).

Results: AANHPI men and women (total 40,740 deaths) had lower all-sites-combined cancer mortality rates (128.3 and 92.4 per 100,000, respectively) than NHWs (185.3 and 140.6) but higher mortality for nasopharynx, stomach, and liver cancers. Among AANHPIs, both NHOPIs and Southeast Asians had the highest overall rates including for colorectal, lung (men only), and cervical cancers; South Asians had the lowest. NHOPI women had 41% higher overall mortality

Corresponding Author Heidy N. Medina, Department of Public Health Sciences, University of Miami Miller School of Medicine, Clinical Research Building, 1120 N.W. 14th Street, Miami, FL 33136, Phone Number: 239-285-4340, h.medina3@umiami.edu.

Author Contributions:

Heidy N. Medina: Conceptualization, Formal analysis, Writing - Original Draft, Writing - Review and Editing. **Karen E. Callahan:** Conceptualization, Formal analysis, Writing - Original Draft, Writing- Review and Editing. **Cyllene R. Morris:** Formal analysis, Writing- Review and Editing. **Caroline A. Thompson:** Formal analysis, Writing- Review and Editing. **Adugna Siweya:** Visualization, Writing- Review and Editing. **Paulo S. Pinheiro:** Conceptualization, Methodology, Formal analysis, Writing - Original Draft, Writing- Review and Editing, Supervision

Conflict of Interest Statement: The authors declare no potential conflicts of interest.

than NHWs (MRR:1.41;95%CI:1.25–1.58), including for breast (MRR:1.33; 95%CI:1.08–1.65) and markedly higher for endometrial cancer (MRR:3.34; 95%CI:2.53–4.42).

Conclusions: AANHPI populations present with considerable heterogeneous cancer mortality patterns. Heightened mortality for infection, obesity, and tobacco-related cancers in Southeast Asians and NHOPI populations highlight the need for differentiated priorities and public health interventions among specific AANHPI populations.

Impact: Not all AANHPIs have favorable cancer profiles. It is imperative to expand the focus on the currently understudied populations that bear a disproportionate cancer burden.

Keywords

cancer; mortality; Asian; Chinese; Filipino; South Asian; Vietnamese; Korean; Japanese; Southeast Asian; Native Hawaiian; Pacific Islander

Introduction

Asian American and Native Hawaiian/Pacific Islanders (AANHPI) are 24.7 million and account for 6% of the United States population (1,2). As the fastest growing major racial/ethnic group, AANHPIs are projected to comprise 10% of the US population by 2060 (1,3). At times described as the “model minority”, AANHPIs, in aggregate, have relatively favorable socioeconomic and health profiles (4). Notwithstanding, cancer has been the leading cause of death for AANHPIs since the year 2000 (5). As immigration increases (1) and the older population expands (6), the AANHPI cancer burden will increase concomitantly.

With ancestry in numerous countries of origin, remarkable heterogeneity exists within the AANHPI designation. The six largest groups among AANHPI are Chinese, South Asian, Filipino, Vietnamese, Korean, and Japanese (1) followed by the less commonly studied Native Hawaiian and Other Pacific Islander (NHOPI) population (7). Differences in culture, nativity, migration history, English language proficiency, dietary practices, educational attainment, occupation type, and other factors impact their overall health as well as cancer-specific risk factors (8–13). As such, researchers have been advocating for the presentation of cancer indicators by unique racial group for AANHPIs (14–18).

Cancer mortality is a population-based indicator that reflects both cancer incidence and survival. Importantly, for states that provide birthplace information along with detailed race for decedents upon request, mortality data is uniquely suited for accurate disaggregation (19) into AANHPI specific group, minimizing misclassification and without the need for imputation (20). In the current study, we aim to characterize the most recent cancer mortality patterns (2012–2017) across major cancer sites for AANHPI groups residing in California, home to one-third of all AANHPIs in the US. By using the same geographical area, the study avoids potential bias by region. Notably, in addition to the six largest AANHPI groups often studied, we include two growing populations often excluded in mortality studies that disaggregate AANHPIs due to relatively fewer cancer deaths: Southeast Asian (grouping Cambodian, Hmong, Laotian and Thai) and NHOPIs. These exclusions obfuscate their unique cancer challenges.

Methods

Six years of complete cancer mortality data, from January 1, 2012, through December 31, 2017, were obtained from the California Department of Public Health. Age, sex, education level, race/ethnicity, birthplace, and underlying cause of death of the decedent were examined. Included decedents were California residents whose primary cause of death was any malignant neoplasm, inclusive of ICD-10 codes C00-C97 (21). All-sites-combined cancer deaths were analyzed, as well as 19 of the most common cancer sites.

Cancer mortality rates were examined for the majority non-Hispanic White (NHW) population, as well as for the AANHPI population in aggregate and 8 distinct groups: Chinese, Filipino, South Asian, Vietnamese, Korean, Japanese, Southeast Asian, and NHOPI. The combined AANHPI population included all aforementioned detailed racial groups as well as decedents from other specified AANHPI (n=266; 0.1%) and unspecified AANHPIs (n=500; 1.2%). South Asians included decedents of Indian race primarily from India but also other from countries (US, Fiji, Kenya, etc.), in addition to decedents from Pakistan, Nepal, Bangladesh, and Sri Lanka as categorized in previous studies (22). Southeast Asians included primarily Cambodian, Laotian, Hmong, and Thai decedents. NHOPI included Samoan, Native Hawaiian, Guamanian, Tongan, and Fijian decedents, as well as those from any other Polynesian, Micronesian, and Melanesian islands and nations. Multiple-race AANHPI (e.g., Chinese-Cambodian or Filipino-Hawaiian) decedents were assigned according to primary race reported (Race 1) following the practice of previous population-based studies (23,24). These subjects constituted only a small proportion of all AANHPIs in this study (n=1,271; 3.1%). Multiracial AANHPIs that reported non-AANHPI races (i.e., White, Black, American Indian) were excluded (n=1,323).

Population denominators were obtained from the US Census Bureau, using 2012 to 2017 pooled single-year American Community Survey data (25) (Table 1). For the six-year period, cancer mortality rates were calculated per 100,000 persons, sex-stratified, annualized, and age-standardized to the 2000 US Standard Population (Table 2 and Table 3). Eighteen 5-year age-group bands (except the last; 85 and older) were used; 95% confidence intervals were calculated using Gamma intervals modification (26). For South Asian, Southeast Asian, and NHOPI specific subgroups (e.g., Nepalese, Thai, Samoan) with small numbers of cancer deaths and small population sizes, rates could be less reliable and therefore heterogeneity by cancer site was presented as proportions of cancer deaths only (Supplementary Table 1 and 2).

For direct comparisons of mortality rates, we computed sex-stratified, age-adjusted, cancer site-specific mortality rate ratios (MRRs) using negative binomial regression (27) which is more effective than the US Standard population weights in combining age-specific ratios of populations with distinct age structures. Decedents ages 35 and older were included in the models, except for prostate cancer, which included ages 45 and older (Table 4).

SAS 9.4 was used for data analyses. Institutional Review Board approval was obtained from the California Department of Public Health.

Results

A total of 260,914 cancer deaths in California from 2012–2017 were analyzed: 84% among NHWs and 16% among AANHPI (Table 1). Among AANHPI decedents, the largest represented groups were Chinese and Filipino, with 12,101 and 10,032 cancer deaths, respectively, in the six-year period. Considerable socio-demographic heterogeneity was evident as shown in Table 1. The proportion of college-educated decedents was slightly lower among AANHPIs (53%) than NHWs (55%). However, tremendous variation existed by distinct AANHPI group, ranging from 71% among Filipinos to 27% among Southeast Asians. Among each AANHPI group, over 90% of cases were foreign-born, with the exception of NHOPI with 65% (partly due to inclusion of Native Hawaiians in this group) and Japanese with only 37% (Table 1).

Among NHW and AANHPI men in aggregate, the top cause of cancer death (computed as a percent of total cancer deaths) was lung cancer, with colorectal, liver, pancreas, and prostate cancers also in the top five for both groups. By distinct AANHPI group, lung cancer was still the leading cause of cancer mortality, accounting for 16%−29% of cancer deaths, along with colorectal and pancreas cancers which ranked in the top five. Liver cancer, accounting for 9%−21% of all cancer deaths depending upon the group, was either the second or third leading cause of death for all AANHPI races except Japanese. Prostate cancer did not rank in the top five for Vietnamese, Koreans, or Southeast Asians. Stomach cancer, ranking only 14th for NHWs, was fourth or fifth for Japanese, Korean, and Vietnamese men. Additionally, oral cancer was the fifth leading cause of cancer mortality for Southeast Asian men (Table 2). Among groups that represent more than one country of origin (i.e., South Asians, Southeast Asians, and NHOPI), there was considerable within group heterogeneity in the proportion of deaths by cancer type (Supplementary Table 1 and Supplementary Table 2).

Among women, lung and breast were leading causes, accounting for almost half of all cancer deaths among NHW women. For AANHPI women, in aggregate and for each group, lung and breast accounted for 27%−35% of all cancer deaths. Colorectal and pancreas were also in the top five leading causes for all analyzed groups. Liver cancer ranked only tenth among NHW women but was the fifth leading cause of cancer death for AANHPI women in aggregate, the third leading cause among Southeast Asian women, fourth for Vietnamese, and fifth for Chinese. Stomach cancer was the fifth leading cause of cancer death among Korean and Japanese women; ovarian cancer was second for South Asians and fifth for Filipinas. Among NHOPI women, endometrial cancer ranked as their fourth leading cause, accounting for 9% of all cancer deaths (Table 3).

In aggregate, AANHPI men and women had lower all-sites-combined cancer mortality rates per 100,000 (128.3, 95%CI: 126.5–130.1; 92.4, 95%CI: 91.1–93.7, respectively) than NHWs (185.3, 95% CI: 184.2–186.4; 140.6, 95% CI: 139.7–141.5, respectively). Among all analyzed AANHPI groups, the highest all-sites-combined cancer mortality rates were seen among NHOPI and Southeast Asian men (174.9, 95%CI: 160.4–190.2; 176.3, 95%CI: 164.1–189.1, respectively) (Table 2) and women (177.3, 95%CI: 164.4–190.9; 112.3, 95%CI 104.8–120.5, respectively) (Table 3); South Asians had the lowest (75.2, 95%CI: 70.6–80.1 in males and 65.9, 95%CI: 61.8–71.2 in females). AANHPI men and women had lower

cancer mortality than NHWs for most analyzed cancers, with the exception of the cancers associated with infections: stomach, liver, nasopharynx, and cervical. Among both men and women, the highest stomach cancer rates were among Koreans. Southeast Asian, Vietnamese, and Korean men and women had the highest liver cancer rates. Nasopharynx cancer mortality rates were highest among Southeast Asian men and Chinese women. The highest cervical cancer mortality was among NHOPI and Southeast Asian women.

Comparisons with the NHW reference group showed lower all-sites combined cancer mortality for AANHPIs in aggregate (male MRR 0.70, 95%CI: 0.69–0.72; female MRR 0.68, 95%CI: 0.61–0.75) and the majority of AANHPI groups. AANHPIs had significantly higher nasopharynx, stomach, and liver cancer mortality compared to NHWs (Supplementary Table 3). Examined by distinct group, no significant differences in overall mortality were found between Southeast Asians (both sexes) and NHOPI men compared to NHWs. NHOPI women had a 41% greater overall cancer mortality than their NHW counterparts (MRR: 1.41, 95% CI: 1.25–1.58). By cancer site, Southeast Asian men and women had the greatest mortality for oral cavity and pharynx (1.6 and 2.1 times greater, respectively) and liver cancer (4.4 and 3.3 times higher). Southeast Asian men also had higher mortality for colorectal and lung cancer (MRR:1.46, 95%CI: 1.21–1.76 and MRR:1.27, 95%CI: 1.06–1.51, respectively) compared to NHW men. Further, NHOPI women had higher colorectal, breast, cervical, and endometrial cancer mortality compared to NHW women, 1.5, 1.3, 7.1, and 3.3 times higher, respectively. Likewise, Korean men and women had greater stomach cancer mortality, with rates 4.4 and 5.2 times higher, respectively, than NHWs (Table 4). Key findings are summarized in Table 5.

Discussion

To our knowledge, this study represents the most recent population-based analysis of cancer data on the fastest growing minority group in the US. AANHPIs in California had lower all-combined rates for most cancers including the four main sites, prostate, breast, colorectal, and lung, but uniformly higher mortality rates for liver and stomach cancers in each AANHPI group except South Asians. The liver cancer excess mortality among AANHPIs (28) has been attributed to the high prevalence of chronic infection by Hepatitis B among AANHPI populations. As previously established (28), the low mortality observed among South Asian and Japanese males is in contrast to the very high rates for Vietnamese. In this study, we found that rates for Southeast Asians, originally from the same geographic region, actually exceeded those of Vietnamese in the US. Overall, our results are consistent with previous mortality studies (5,29–33) and mirror the relative differences in AANHPI populations found in previous incidence reports (5,22,30,32–35). Moreover, our findings parallel those observed for AANHPI in other states with large proportions of these populations, such as Hawaii (36). Previously observed excess burden for some specific cancer sites, including very high rates for nasopharynx among Chinese, stomach for Koreans, and liver for Vietnamese (22), persisted in the recent period (2012–2017) studied here.

In the current study, we further update and expand on previously reported mortality data for two often overlooked and understudied AANHPI groups with distinct, unfavorable patterns,

even for non-infection related cancers: NHOPIs and Southeast Asians, for which an excess mortality burden has been documented (5,30). These two groups had the highest cancer mortality rates of all the AANHPI groups, particularly high for NHOPI females.

The Southeast Asian group is itself comprised of heterogeneous populations, including Laotians, Hmong, Cambodians, and Thais. Combined, they represent a relatively small US population, approximately 1.6 million (2), whose specific needs may be overlooked when grouped with the more favorable cancer mortality profiles of other more populous AANHPI groups such as Chinese and South Asians. This conceals their specific cancer vulnerabilities: overall cancer mortality rates were quite high compared to other AANHPI groups, particularly for lung and oral cancers. Except for Thais, Southeast Asians (i.e., Cambodians, Hmong, and Laotians) have been documented with the lowest educational attainment among all Asian subgroups in the US (4), which has been shown to be associated with a higher risk of cancer death for nearly all cancers (37). This disparity along with the high poverty rates observed for these populations (4) may further influence cancer mortality disparities due to smoking, obesity, physical inactivity, diet, alcohol use, screening, and treatment (38). Given the documented high prevalence of tobacco use, both smoked and smokeless (e.g., chewing), among Southeast Asian men and women (39,40) the excessive lung and oral cancer mortality rates are not entirely surprising. In this respect, further investigation into the types and frequency of tobacco use as well as the efficacy of existing smoking cessation programs and other interventions are warranted. Moreover, the high mortality for both colorectal and cervical cancer among Southeast Asians suggests they could benefit from more culturally specific approaches to existing cancer screening programs. High liver cancer mortality among Southeast Asians highlights the persistent need for Hepatitis B testing/screening in all AANHPI populations but particularly those consisting of more recent immigrants. Targeted public health interventions may be of particular benefit to this group.

Similarly to Southeast Asians, the NHOPI population of approximately 1.5 million is relatively small (2) but nonetheless of importance in disentangling AANHPI cancer mortality disparities. Among AANHPI groups, NHOPI men had relatively high cancer mortality rates, but it is among females that this excess is particularly worrying as they have very high rates, not only higher in comparison to other AANHPI groups but also in relation to NHWs. Uniquely, all-sites-combined cancer mortality for NHOPIs was similar among men and women. This unusual pattern, rarely seen in any racial/ethnic group, can be attributed to the excessive breast and endometrial cancer mortality in women, burdensome enough to counterbalance the lung and prostate cancer mortality among men. Excessive high lung cancer mortality for both males and females mirrored their reported high smoking prevalence (41). Previous research has shown that Native Hawaiians have a higher degree of susceptibility to lung cancer in comparison to Whites, Hispanics, and Japanese Americans, which cannot be accounted for by differences in sociodemographic and lifestyle-related risk factors (42). Similarly, in our study, Native Hawaiians were the NHOPI group with the highest proportion of deaths due to lung cancer (Supplementary Table 2). Moreover, colorectal and prostate cancer mortality was also remarkably high and NHOPI women were also burdened by high mortality for breast, cervical, and endometrial. Therefore, making the NHOPI population one of the most cancer-affected groups in the US. The preponderance of colorectal, breast, and endometrial cancers may be a direct result of the high prevalence of

obesity (43–45), the highest among all racial/ethnic groups in the US with the exception of American Indian adults (46). Obesity is a known cancer risk factor for these cancers and is a determinant of poor cancer survival (45,47). Together, these likely explain the high population-based mortality rates seen here (45,47). Further, low uptake of routine cancer screenings, including Papanicolaou (Pap) tests for cervical cancer, mammograms for breast cancer, and colonoscopies for colorectal cancer, has been documented for the NHOPI group (48). Notably, in general health surveys, NHOPIs were also found to be more likely to report their overall health as fair or poor and to be bedridden because of illness or disability (49). As is the case with Southeast Asians, the excess in risk factors aforementioned for NHOPIs is influenced by their lower level of education, a higher rate of poverty, and greater uninsured population in comparison to Whites in the US (50). Given the substantial cancer mortality excess revealed among NHOPI in this study, the inclusion of their unique cancer experience as a disaggregated group from Asian Americans is an area of opportunity for cancer prevention.

Few studies discuss the cancer mortality burden among South Asians, comprised primarily of Indians and currently the second largest AANHPI group in the US, surpassing Filipinos and second only to Chinese (1). This apparent oversight is likely due to the fact that cancer does not appear to be a prominent concern for South Asians on a population basis, despite being highly afflicted by heart disease and diabetes (51,52). Their low cancer mortality was evident across cancers common to all race/ethnicities (i.e., breast, lung, colorectal, and prostate) as well as those typically more common in other AANHPI groups: stomach and liver. For stomach cancer, the paradox observed among African populations in which low rates of stomach cancer are observed in the context of a high prevalence of *H.pylori* infection (53), may extend to South Asians. Combined with unusually low colorectal cancer mortality, these patterns also suggest that South Asian populations could be suitable for exploratory research into the impact of dietary practices, quite unique in this group, on cancers of the digestive tract. Liver cancer mortality rates were also low for South Asians, possibly attributable to lower HBV prevalence among this population in the US (28). Although the different causes of liver cancer have been extensively examined among Hispanic groups (54), they have not been studied by specific AANHPI populations. Moreover, low lung cancer mortality is consistent with historically lower smoking prevalence in South Asians in comparison to other AANHPI groups (55). Moreover, and in apparent contradiction with their lower mortality rates, South Asians have lower proportions of cancer screening than other AANHPI groups (56,57), although there has been a significant increase in uptake of screening for some sites, such as colorectal cancer (58). Nonetheless, since the South Asian population in California may not reflect the full socioeconomic spectrum of South Asians across the US, other studies should be conducted to confirm these relatively favorable mortality findings in this population.

Since many AANHPIs are foreign-born, evaluating the impact of immigrant status and duration of stay on cancer patterns in the US is important (49). Japanese Americans, who had the highest US-born population proportion in our study, and Filipinos, who have historically been more fluent in English and demonstrate higher scores of acculturation than any other AANHPI group (59,60) showed lower cancer mortality than NHWs and lower or similar mortality to other AANHPI groups for all-sites-combined. Further, Japanese men

and women show the highest proportion of colorectal and breast cancer screening, respectively, within AANHPI subgroups (56,57). Nonetheless, although length of stay information is not available in mortality data, our patterns suggest that acculturation does not adversely impact AANHPI cancer mortality as much as has been documented among Mexican Hispanics (61) or Afro-Caribbeans (62).

The main strength of this study is the ability to circumvent the problem of selection bias inherent in other epidemiologic study designs by using complete population-based data that includes every event of interest, in this case, every death. This is, to our knowledge, the most recent study comparing disaggregated cancer mortality patterns in a highly diverse group, the AANHPI. Data completeness, over 99% for race/ethnicity and birthplace variables for AANHPI cancer deaths in California allowed for accurate classification into specific groups. Additionally, we took the opportunity to examine two groups that have been largely overlooked in previous mortality analyses: Southeast Asians and NHOPIs. The state of California, comprising almost 30% of the AANHPI population in the US, also includes an even larger proportion of older individuals more prone to death by cancer, compared to any other state in the country. Thus, California adequately represents this group in overall population size and age structure and can be considered ideal for studying cancer mortality patterns in AANHPI populations in order to identify any disparities.

As with any study, some limitations should be noted. There is a potential for misclassification of race/ethnicity; however, prior research comparing California death certificate birthplace information with self-reported interview data for AANHPI populations (including Filipino, Chinese, Japanese, Vietnamese, Southeast Asian) has found that death certificate birthplace data is complete and accurate and therefore research incorporating this data can be conducted reliably for these populations (63). The two groups of focus, Southeast Asians and NHOPIs, are themselves heterogeneous and often of combined races (multiracial). In aggregating these heterogeneous groups, which is necessary to highlight their overall plight, there may be a failure in capturing unique specificities among each subgroup, although these patterns may be difficult to assess due to small numbers. NHOPI, for example, are highly heterogeneous and include Native Hawaiians, Guamanians, Tongans, Samoans, and non-Hindu Fijians; they are also overwhelmingly multi-racial (64). Some disparities in cancer incidence according to disaggregated NHOPI groups have been previously identified (35), and are consistent with our mortality findings. Most striking is the proportional preponderance of cancer deaths due to breast and endometrial cancers among Tongans, Samoans, and Fijians, which was not seen among Native Hawaiians or Guamanians (Supplementary Table 2). Additionally, the Salmon Bias, in which those with deteriorated health may return to their home countries of origin to die (65), may cause an underestimation in mortality rates for AANHPI immigrants. Mortality as an outcome measure is a function of population-level, all-stages combined incidence and survival; the extent to which each factor into the patterns observed is unclear. For instance, the Southeast Asian group includes refugee immigrants (66) who may be less educated and more economically challenged than other AANHPI groups (67), which may translate into survival disadvantages that could impact their mortality rate on a population basis. Additionally, there is possible misclassification arising from the methodology used to assign decedents reporting multiple races, but this was unlikely to bias our results since multiracial subjects

only accounted for a small proportion of our sample. Further research among multiracial AANHPIs is needed. Lastly, mortality data does not contain individual-level information on risk factors, comorbidities, screening, or treatment-related characteristics.

In conclusion, the current study characterizes the distinct cancer mortality profiles among the heterogenous AANHPI population in California. Similarities were found for many of the groups, such as high mortality rates for stomach and liver cancers and relatively lower rates for breast and prostate. On the other hand, some important disparities between groups were noted, such as the high lung and colorectal cancer mortality among both Southeast Asians and NHOPIs. In particular, our study identified a disproportionate burden of breast and endometrial cancers among NHOPI women. Despite the fact that mortality for the most common cancers is decreasing, it is increasing for some sites (e.g., liver and endometrial) (68) and the profiles have only partially been studied in these heterogenous groups. Overall, for the infrequently studied populations that we identified as facing the largest cancer burden, Southeast Asians and NHOPIs, additional focus is required to better understand the etiology of all cancers, in general, and identify areas of intervention, prevention, and control. This complex context highlights the need for a timely characterization of not only their mortality patterns but also incidence and survival.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support: P.S. Pinheiro received supplemental funding from the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. P.S. Pinheiro was also supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA240139. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Budiman A, Cilluffo A, Ruiz NG. Key Facts about Asian origin groups in the US. Pew Research Center; 2019. Available from https://www.pewresearch.org/fact-tank/2017/09/08/key-facts-about-asian-americans/.
2. US Census Bureau. 2018 American Community Survey, 1-Year Estimates, Table B02018: Asian Alone or in Any Combination and Table B02019: Native Hawaiian and Other Pacific Islander Alone or in Any Combination. Available from www.census.gov/acs. Accessed September 2020.
3. Colby SL, Ortman JM. Projections of the Size and Composition of the US Population: 2014 to 2060. Washington, DC: US Department of Commerce; Economics and Statistics Administration; US Census Bureau; 2015. Available from https://www.census.gov/content/dam/Census/library/publications/2015/demo/p25-1143.pdf.
4. López G, Ruiz NG, Patten E. Key facts about Asian Americans, a diverse and growing population. Pew Research Center; 2017. Available from https://www.pewresearch.org/fact-tank/2017/09/08/key-facts-about-asian-americans/.
5. Torre LA, Sauer AM, Chen MS, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin 2016;66(3):182–202. [PubMed: 26766789]

6. Administration for Community Living, U.S. Department of Health and Human Services. 2018 Profile of Asian Americans Age 65 and Over. Available from https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2018AsA_OAProfile.pdf.
7. Hixson LK, Hepler BB, Kim MO. The native Hawaiian and other Pacific Islander population: 2010. US Department of Commerce, Economics and Statistics Administration, US; 2012. Available from https://www.census.gov/content/dam/Census/library/publications/2012/dec/c2010br-12.pdf.
8. Blane D Social determinants of health--socioeconomic status, social class, and ethnicity. Am J Public Health 1995;85(7):903–5. [PubMed: 7604907]
9. Yu ES. The health risks of Asian Americans. Am J Public Health 1991;81(11):1391–3. [PubMed: 1951791]
10. California Health Interview Survey. CHIS 2012 Adult Public Use File. Los Angeles,CA: UCLA Center for Health Policy Research; 2014. Available from https://healthpolicy.ucla.edu/chis/data/Pages/GetCHISData.aspx. Accessed October 2020.
11. Tseng W, McDonnell DD, Takahashi L, Ho W, Lee C, Wong S. Ethnic Health Assessment For Asian Americans, Native Hawaiians, And Pacific Islanders in California. Berkley, CA: UCLA School of Public Health; 2010. Available from https://www2.jabsom.hawaii.edu/native/docs/publications/2010/Ethnic_Health_Assessment_for_Asian_Americans,_NHs,_&_PIs_in_California_8-10.pdf.
12. Chang ET, Yang J, Alfaro-Velcamp T, So SKS, Glaser SL, Gomez SL. Disparities in Liver Cancer Incidence by Nativity, Acculturation, and Socioeconomic Status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev 2010;19(12):3106–18. [PubMed: 20940276]
13. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85(22):1819–27. [PubMed: 8230262]
14. Stafford S Caught between “The Rock” and a hard place: the native Hawaiian and Pacific Islander struggle for identity in public health. Am J Public Health 2010;100(5):784–9. [PubMed: 20388621]
15. Holland AT, Palaniappan LP. Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation. Annals of Epidemiology 2012;22(6):397–405. [PubMed: 22625997]
16. Srinivasan S, Guillermo T. Toward improved health: disaggregating Asian American and Native Hawaiian/Pacific Islander data. Am J Public Health 2000;90(11):1731–4. [PubMed: 11076241]
17. Gomez SL, Glaser SL, Horn-Ross PL, Cheng I, Quach T, Clarke CA, et al. Cancer research in Asian American, Native Hawaiian, and Pacific Islander populations: accelerating cancer knowledge by acknowledging and leveraging heterogeneity. Cancer Epidemiol Biomarkers Prev 2014;23(11):2202–5. [PubMed: 25368394]
18. Panapasa SV, Crabbe KM, Kaholokula JK. Efficacy of Federal Data: Revised Office of Management and Budget Standard for Native Hawaiian and Other Pacific Islanders Examined. AAPI Nexus 2011;9(1–2):212–20. [PubMed: 25360070]
19. Pinheiro PS, Callahan KE, Kobetz EN. Disaggregated Hispanic Groups and Cancer: Importance, Methodology, and Current Knowledge. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos. Cham: Springer International Publishing; 2020. p 17–34.
20. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The validity of race and Hispanic origin reporting on death certificates in the United States. Vital Health Stat 2 2008; (148):1–23.
21. World Health Organization. International statistical classification of diseases and health related problems: ICD-10. Geneva: World Health Organization; 2004. Available from https://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf.
22. Jin H, Pinheiro PS, Xu J, Amei A. Cancer incidence among Asian American populations in the United States, 2009–2011. Int J Cancer 2016;138(9):2136–45. [PubMed: 26661680]
23. North American Association of Central Cancer Registries. Standards for Cancer Registries,Data Standards and Data Dictionary (Version 15). Available from http://www.naaccr.org/Applications/ContentReader/Default.aspx?c=10.

24. North American Association of Central Cancer Registries. Asian/Pacific Islander Identification Algorithm [NAPIIA v1.2.1]: Enhancing the specificity of identification. Available from https://www.naaccr.org/LinkClick.aspx?fileticket=3HnBhlmhkBs%3D&tabid=92&mid=432.
25. Ruggles S, Flood S, Goeken R, Grover J, Meyer E, Pacas J, et al. IPUMS USA: Version 9.0 [dataset]. In: IPUMS, editor. Minneapolis, MN; 2019. Available from 10.18128/D010.V9.0. Accessed August 2020.
26. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 2006;15(6):547–69. [PubMed: 17260923]
27. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull 1995;118(3):392–404. [PubMed: 7501743]
28. Pinheiro PS, Callahan KE, Jones PD, Morris C, Ransdell JM, Kwon D, et al. Liver cancer: A leading cause of cancer death in the United States and the role of the 1945–1965 birth cohort by ethnicity. JHEP Reports 2019;1(3):162–9. [PubMed: 32039366]
29. Huang V, Li W, Tsai J, Begier E. Cancer Mortality among Asians and Pacific Islanders in New York City, 2001–2010. J Cancer Epidemiol 2013;2013:986408.
30. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 2008;19(3):227–56. [PubMed: 18066673]
31. Thompson CA, Gomez SL, Hastings KG, Kapphahn K, Yu P, Shariff-Marco S, et al. The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity. Cancer Epidemiol Biomarkers Prev 2016;25(10):1371–82. [PubMed: 27694108]
32. McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007;57(4):190–205. [PubMed: 17626117]
33. Kwong SL, Chen M, Snipes KP, Bal DG, Wright WE. Asian subgroups and cancer incidence and mortality rates in California. Cancer 2005;104(12 Suppl):2975–81. [PubMed: 16247792]
34. Gomez SL, Noone AM, Lichtensztajn DY, Scoppa S, Gibson JT, Liu L, et al. Cancer incidence trends among Asian American populations in the United States, 1990–2008. J Natl Cancer Inst 2013;105(15):1096–110. [PubMed: 23878350]
35. Liu L, Noone A-M, Gomez SL, Scoppa S, Gibson JT, Lichtensztajn D, et al. Cancer Incidence Trends Among Native Hawaiians and Other Pacific Islanders in the United States, 1990–2008. J Natl Cancer Inst 2013;105(15):1086–95. [PubMed: 23878354]
36. Loo LWM, Williams M, Hernandez BY. The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. Cancer Epidemiol 2019;58:71–6. [PubMed: 30503975]
37. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin 2018;68(5):329–39. [PubMed: 30191964]
38. Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950–2014: Over Six Decades of Changing Patterns and Widening Inequalities. Journal of Environmental and Public Health 2017; 2819372.
39. Sreeramareddy CT, Pradhan PMS, Mir IA, Sin S. Smoking and smokeless tobacco use in nine South and Southeast Asian countries: prevalence estimates and social determinants from Demographic and Health Surveys. Popul Health Metr 2014;12:22. [PubMed: 25183954]
40. Cheong SC, Vatanasapt P, Yi-Hsin Y, Zain RB, Kerr AR, Johnson NW. Oral cancer in South East Asia:Current status and future directions. Translational Research in Oral Oncology 2017;2:2057178X17702921.
41. Mukherjea A, Wackowski OA, Lee YO, Delnevo CD. Asian American, Native Hawaiian and Pacific Islander tobacco use patterns. Am J Health Behav 2014;38(3):362–9. [PubMed: 24636032]
42. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354(4):333–42. [PubMed: 16436765]
43. Singh GK, Lin SC. Dramatic Increases in Obesity and Overweight Prevalence among Asian Subgroups in the United States, 1992–2011. ISRN Preventive Medicine 2013;2013:898691.

44. Centers for Disease Control and Prevention. Summary Health Statistics: National Health Interview Survey: 2016. Table A-15a.Available from https://www.cdc.gov/nchs/nhis/shs/tables.htm. Accessed September 2020.
45. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. Journal of Obesity 2013;2013:291546.
46. Subica AM, Agarwal N, Sullivan JG, Link BG. Obesity and Associated Health Disparities Among Understudied Multiracial, Pacific Islander, and American Indian Adults. Obesity 2017;25(12):2128–36. [PubMed: 29071803]
47. Ellis L, Woods LM, Estève J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: Explaining the concepts. Int J Cancer 2014;135(8):1774–82. [PubMed: 24945976]
48. Thompson CA, Gomez SL, Chan A, Chan JK, McClellan SR, Chung S, et al. Patient and provider characteristics associated with colorectal, breast, and cervical cancer screening among Asian Americans. Cancer Epidemiol Biomarkers Prev 2014;23(11):2208–17. [PubMed: 25368396]
49. Frisbie WP, Cho Y, Hummer RA. Immigration and the health of Asian and Pacific Islander adults in the United States. Am J Epidemiol 2001;153(4):372–80. [PubMed: 11207155]
50. US Department of Health and Human Services Office of Minority Health. Minority Population Profiles:Native Hawaiians/Pacific Islanders. Available from https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=65.
51. Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep 2014;16(5):476. [PubMed: 24643902]
52. Palaniappan L, Garg A, Enas E, Lewis H, Bari S, Gulati M, et al. South Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology. J Community Health 2018;43(6):1100–14. [PubMed: 29948525]
53. Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter Pylori associated global gastric cancer burden. Front Biosci 2009;14:1490–504.
54. Pinheiro PS, Medina HN, Callahan KE, Jones PD, Brown CP, Altekruse SF, et al. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int 2020; 40(5):1201–1210. [PubMed: 32087002]
55. Mukherjea A, Modayil MV. Culturally Specific Tobacco Use and South Asians in the United States:A Review of the Literature and Promising Strategies for Intervention. Health Promotion Practice 2013;14(5_suppl):48S–60S. [PubMed: 23690257]
56. Lee HY, Lundquist M, Ju E, Luo X, Townsend A. Colorectal cancer screening disparities in Asian Americans and Pacific Islanders: which groups are most vulnerable? Ethn Health 2011;16(6):501–18. [PubMed: 22050536]
57. Lee HY, Ju E, Vang PD, Lundquist M. Breast and cervical cancer screening disparity among Asian American women: does race/ethnicity matter? J Womens Health 2010;19(10):1877–84.
58. Fedewa SA, Sauer AG, Siegel RL, Smith RA, Torre LA, Jemal A. Temporal Trends in Colorectal Cancer Screening among Asian Americans. Cancer Epidemiol Biomarkers Prev 2016;25(6):995–1000. [PubMed: 27197273]
59. Espiritu YL. Home bound: Filipino American lives across cultures, communities, and countries. Berkeley: University of California Press; 2003.
60. Ling H, Austin A. Asian American History and Culture: An Encyclopedia. New York: Routledge; 2015.
61. Pinheiro PS, Callahan KE, Stern MC, de Vries E. Migration from Mexico to the United States: A high-speed cancer transition. Int J Cancer 2018;142(3):477–88. [PubMed: 28940515]
62. Pinheiro PS, Callahan KE, Ragin C, Hage RW, Hylton T, Kobetz EN. Black Heterogeneity in Cancer Mortality: US-Blacks, Haitians, and Jamaicans. Cancer Control 2016;23(4):347–58. [PubMed: 27842324]
63. Gomez SL, Glaser SL. Quality of birthplace information obtained from death certificates for Hispanics, Asians, and Pacific Islanders. Ethn Dis 2004;14(2):292–5. [PubMed: 15132217]
64. Humes KR, Jones NA, Ramirez RR. Overview of Race and Hispanic Origin: 2010. US Census Bureau; 2011. Available from http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf.

65. Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr 2014;2014(49):210–7. [PubMed: 25417234]

66. O'Hare WJ. A new look at poverty in America. Popul Bull 1992;51:1–47.

67. Southeast Asia Resource Action Center. Overview of Southeast Asian Educational challenges. Washington, DC; 2013. Available from https://vtechworks.lib.vt.edu/bitstream/handle/10919/83656/SoutheastAsianAmericanstudents.pdf?sequence=1&isAllowed=y.

68. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2020;126(10):2225–49. [PubMed: 32162336]

Table 1.

Study population characteristics. California, 2012–2017.

	Population Data, CA 2012–2017			Cancer Deaths, CA 2012–2017		
	Annualized N[a]	Proportion of Total U.S. Population Residing in CA	Median Age (among those over 20)	Number	% At least some college	% Foreign-born
NHW	14,752,057	7.5	50	220,174	55.3	11.4
AANHPI-All	6,221,713	29.6	44	40,740	52.7	86.1
Chinese	1,538,099	35.8	46	12,101	46.7	90.3
Filipino	1,396,110	42.2	45	10,032	70.9	92.6
South Asian	823,840	18.3	38	2,206	57.0	97.0
Vietnamese	695,249	36.7	45	4,257	36.2	98.3
Korean	504,225	30.1	44	3,848	54.9	97.4
Japanese	375,903	32.7	50	4,233	54.4	37.1
Southeast Asian	305,721	33.0	37	1,850	27.1	98.5
NHOPI	191,998	25.5	40	1,447	39.0	65.0

Abbreviations: NHW, non-Hispanic White; AANHPI, Asian American/Native Hawaiian/Pacific Islander; NHOPI, Native Hawaiian and Other Pacific Islander

[a] Ordered from largest to smallest Annualized N

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2021 January 01.

Table 2.

Selected site-specific age-adjusted[a] cancer mortality rates per 100,000 by detailed race group. Male. California 2012–2017.

	NHW		AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)
Oral Cavity & Pharynx	2,950	4.6 (4.4–4.8)	582	3.4 (3.1–3.7)	227	4.4 (3.9–5.1)	96	2.6 (2.1–3.2)	45	2.9 (2.0–3.9)	70	3.3 (2.5–4.2)	25	1.8 (1.2–2.7)	38	2.7 (1.9–3.7)	43	6.3 (4.4–8.7)	24	5.7 (3.6–8.7)
Nasopharynx only	178	0.3 (0.2–0.3)	282	1.5 (1.4–1.7)	145	2.9 (2.4–3.4)	41	1.0 (0.7–1.4)	≠	≠	36	1.6 (1.1–2.2)	≠	≠	≠	≠	31	4.4 (2.9–6.4)	≠	≠
Esophageal	4,528	7 (6.9–7.3)	460	3 (2.5–3.0)	111	2 (1.7–2.5)	99	2 (2.0–3.0)	43	3 (2.0–3.8)	48	2 (1.8–3.3)	39	3 (2.0–3.9)	70	5 (3.8–6.3)	17	3 (1.6–4.7)	21	3 (3.2–8.4)
Stomach	2,200	3.6 (3.4–3.7)	1,104	7.0 (6.5–7.4)	382	7.5 (6.8–8.3)	133	3.8 (3.2–4.6)	28	1.8 (1.1–2.7)	117	6.0 (4.9–7.2)	212	15.9 (13.8–18.2)	154	10.9 (9.2–12.9)	31	6.0 (3.9–8.7)	22	5.8 (3.5–8.9)
Colorectal	9,285	15.1 (14.8–15.4)	2,120	12.9 (12.3–13.5)	663	13.0 (12.0–14.1)	470	12.8 (11.6–14.1)	96	6.1 (4.8–7.5)	229	11.6 (10.1–13.3)	241	17.5 (15.3–19.9)	189	13.2 (11.3–15.4)	116	20.2 (16.3–24.6)	75	19.0 (14.6–24.1)
Liver	5,724	8.6 (8.4–8.8)	2,540	15.1 (14.5–15.7)	756	14.6 (13.6–15.7)	451	12.4 (11.2–13.6)	98	6.2 (5.0–7.7)	535	25.9 (23.7–28.2)	303	21.7 (19.3–24.4)	100	6.7 (5.4–8.3)	197	32.0 (27.2–37.2)	65	14.5 (11.0–18.8)
Pancreas	8,210	13.0 (12.7–13.3)	1,466	9.1 (8.6–9.5)	489	9.5 (8.6–10.4)	309	8.4 (7.4–9.4)	79	5.0 (3.9–6.3)	123	6.3 (5.2–7.6)	174	12.7 (10.9–14.8)	171	11.8 (10.1–13.8)	52	9.6 (6.9–13.0)	37	9.8 (6.7–13.8)
Lung	25,032	39.9 (39.4–40.4)	5,238	32.8 (31.9–33.7)	1,664	32.6 (31.0–34.2)	1,308	37.8 (35.7–40.0)	186	12.3 (10.4–14.3)	732	37.6 (34.8–40.5)	486	36.7 (33.4–40.2)	400	28.2 (25.4–31.2)	238	48.5 (41.9–55.7)	155	44.3 (37.0–52.4)
Prostate	12,887	21.2 (20.8–21.5)	1,389	9.7 (9.2–10.2)	371	7.4 (6.7–8.2)	443	15.5 (14.0–17.1)	116	9.6 (7.8–11.6)	77	4.7 (3.7–5.9)	76	6.6 (5.1–8.3)	181	11.2 (9.6–13.1)	41	9.6 (6.7–13.2)	55	21.8 (16.2–28.4)
Kidney	3256	5.2 (5.0–5.4)	522	3.2 (2.9–3.5)	124	2.4 (2.0–2.9)	158	4.2 (3.6–5.0)	41	2.5 (1.7–3.4)	49	2.3 (1.7–3.0)	59	4.3 (3.3–5.6)	58	4.1 (3.1–5.4)	≠	≠	≠	≠
Bladder	5376	8.8 (8.6–9.0)	469	3.2 (2.9–3.5)	145	2.9 (2.5–3.5)	91	3 (2.4–3.8)	36	2.6 (1.8–3.6)	34	1.9 (1.3–2.7)	62	5 (3.8–6.4)	71	4.7 (3.7–6.0)	≠	≠	≠	≠

	NHW		AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)
Brain	4134	6.9 (6.7–7.1)	498	3 (2.7–3.2)	139	2.9 (2.4–3.4)	118	3.1 (2.6–3.8)	53	2.6 (1.9–3.5)	58	3 (2.3–3.9)	45	3.5 (2.5–4.7)	35	2.6 (1.8–3.7)	20	3.2 (1.9–5.1)	18	3.7 (2.1–5.9)
NHL	4,515	7.4 (7.2–7.6)	834	5.3 (4.9–5.7)	252	5.0 (4.4–5.7)	211	6.2 (5.4–7.2)	59	3.9 (2.9–5.1)	86	4.6 (3.7–5.8)	54	4.0 (3.0–5.3)	101	6.7 (5.4–8.3)	42	7.6 (5.2–10.5)	17	4.5 (2.4–7.4)
Leukemia	5,450	9.2 (8.9–9.4)	799	5.1 (4.7–5.5)	222	4.6 (4.5-.2. 0)	238	7.0 (6.1–8.0)	65	4.1 (3.1–5.3)	101	5.7 (4.6–6.9)	45	3.4 (2.5–4.6)	57	4.1 (3.1–5.4)	29	4.8 (3.1–7.1)	26	6.7 (4.2–10.1)
All-Sites-Combined[c]	114,853	185.3 (184.2–186.4)	20,622	128.3 (126.5–130.1)	6,288	123.6 (120.6–126.8)	4,772	138.2 (134.1–142.3)	1,153	75.2 (70.6–80.1)	2,528	129.3 (124.2–134.7)	2,051	153.1 (146.3–160)	1,860	128.5 (122.5–134.7)	969	176.3 (164.1–189.1)	640	174.9 (160.4–190.2)

Abbreviations: NHL, non-Hodgkin lymphoma; NHW, non-Hispanic White; AANHPI, Asian American/Native Hawaiian/Pacific Islander; NHOPI, Native Hawaiian and Other Pacific Islander

[a] Age-adjusted to the 2000 U.S. Standard Population;

[b] Includes all groups, not only those detailed here;

[c] All-sites-combined includes those listed as well as all others not detailed.

‡ Not reported; rate calculated from observations fewer than 13

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2022 January 01.

Table 3.

Selected site-specific age-adjusted[a] cancer mortality rates per 100,000 by detailed race group. Female. California 2012–2017.

	NHW		AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)
Oral Cavity & Pharynx	1,170	1.6 (1.5–1.6)	264	1.2 (1.1–1.4)	89	1.4 (1.1–1.7)	70	1.2 (1.0–1.6)	≠	≠	25	1.1 (0.7–1.6)	13	0.7 (0.4–1.3)	21	0.7 (0.4–1.2)	25	3.3 (2.1–4.9)	≠	≠
Nasopharynx only	60	0.1 (0.1–0.1)	102	0.5 (0.4–0.6)	51	0.8 (0.6–1.1)	23	0.4 (0.3–0.6)	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠
Esophageal	1,214	1.6 (1.5–1.7)	137	0.6 (0.5–0.7)	40	0.6 (0.4–0.8)	18	0.3 (0.2–0.5)	22	1.4 (0.9–2.2)	≠	≠	≠	≠	33	1.4 (0.9–2.1)	≠	≠	≠	≠
Stomach	1,297	1.7 (1.6–1.8)	985	4.5 (4.3–4.8)	331	5.2 (4.6–5.8)	122	2.1 (1.8–2.6)	27	1.7 (1.1–2.5)	93	0.3 (0.1–0.7)	170	9.0 (7.7–10.5)	144	5.2 (4.3–6.3)	42	5.7 (4.1–7.8)	34	8.1 (5.5–11.5)
Colorectal	9,034	11.8 (11.5–12.0)	2,010	9.2 (8.8–9.6)	585	9.0 (8.3–9.8)	450	8.0 (7.3–8.8)	70	4.8 (3.7–6.2)	194	8.5 (7.3–9.8)	210	11.0 (9.5–12.6)	281	10.4 (9.1–11.9)	116	15.1 (12.4–18.3)	73	17.2 (13.3–21.9)
Liver	2,820	3.7 (3.6–3.8)	1,311	6.1 (5.7–6.4)	347	5.4 (4.8–6.0)	302	5.5 (4.8–6.1)	46	2.7 (1.9–3.6)	179	8.6 (7.4–10.0)	159	8.5 (7.2–9.9)	135	5.4 (4.4–6.5)	87	11.1 (8.8–13.8)	28	6.4 (4.1–9.4)
Pancreas	7,541	9.7 (9.5–9.9)	1,658	7.7 (7.3–8.1)	467	7.4 (6.7–8.1)	420	7.4 (6.7–8.2)	65	4.6 (3.6–5.9)	116	5.3 (4.3–6.3)	199	10.7 (9.2–12.3)	260	10.2 (8.9–11.7)	65	8.3 (6.3–10.6)	42	10.8 (7.6–14.7)
Lung	24,841	32.7 (32.3–33.2)	3,730	17.2 (16.6–17.7)	1,327	20.8 (19.7–22.0)	851	14.8 (13.8–15.9)	97	6.7 (5.4–8.2)	351	15.8 (14.1–17.6)	276	14.8 (13.1–16.6)	461	18.2 (16.4–20.1)	156	20.4 (17.2–24.0)	141	34.6 (28.8–41.1)
Breast	16,425	22.8 (22.4–23.2)	2,868	12.9 (12.5–13.4)	722	11.3 (10.5–12.2)	945	16.3 (15.3–17.4)	209	12.0 (10.4–13.9)	205	8.6 (7.5–10.0)	186	9.5 (8.1–11.0)	296	13.6 (12.0–15.5)	85	10.1 (8.0–12.5)	146	28.8 (24.0–34.2)
Cervix	683	1.3 (1.2–1.4)	443	2.1 (1.9–2.3)	89	1.5 (1.2–1.8)	132	2.5 (2.1–2.9)	16	1.0 (0.6–1.7)	43	1.9 (1.3–2.5)	34	1.8 (1.2–2.5)	31	1.9 (1.2–2.8)	43	5.3 (3.8–7.2)	41	7.4 (5.3–10.2)
Endometrium	3,717	4.9 (4.8–5.1)	801	3.6 (3.3–3.8)	209	3.3 (2.8–3.7)	281	4.7 (4.1–5.3)	49	2.8 (2.0–3.7)	42	1.7 (1.2–2.4)	49	2.5 (1.8–3.3)	60	2.7 (2.1–3.6)	22	2.9 (1.8–4.4)	73	15.1 (11.6–19.3)

	NHW		AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)
Ovary	5,084	7.3 (7.1–7.5)	1,061	4.8 (4.5–5.1)	272	4.3 (3.8–4.9)	305	5.3 (4.7–5.9)	100	5.9 (4.8–7.2)	94	3.9 (3.1–4.8)	98	5.0 (4.1–6.1)	99	4.5 (3.5–5.6)	37	4.5 (3.1–6.3)	32	5.7 (3.8–8.3)
Kidney	1,629	2.1 (2.0–2.3)	270	1.2 (1.1–1.4)	89	1.4 (1.1–1.7)	72	1.3 (1.0–1.6)	21	1.4 (0.9–2.2)	≠	≠	25	1.3 (0.8–1.9)	25	0.9 (0.5–1.4)	≠	≠	≠	≠
Bladder	1,898	2.3 (2.2–2.4)	193	0.9 (0.7–1.0)	68	1.0 (0.8–1.3)	26	0.5 (0.3–0.7)	≠	≠	15	0.7 (0.4–1.2)	22	1.2 (0.8–1.9)	41	1.3 (0.9–1.9)	≠	≠	≠	≠
Brain	3,048	4.5 (4.3–4.7)	432	2.0 (1.8–2.2)	113	1.9 (1.6–2.3)	112	2.1 (1.7–2.5)	53	2.8 (2.0–3.6)	61	2.8 (2.1–3.6)	25	1.3 (0.9–2.0)	29	1.2 (0.7–1.8)	17	2.4 (1.4–3.9)	15	2.8 (1.5–4.8)
NHL	3,480	4.5 (4.3–4.6)	699	3.3 (3.0–3.5)	204	3.2 (2.8–3.7)	211	3.8 (3.3–4.4)	38	2.8 (2.0–3.8)	44	2.2 (1.5–2.9)	42	2.3 (1.6–3.1)	98	3.4 (2.7–4.3)	25	3.3 (2.1–4.8)	24	5.6 (3.4–8.4)
Leukemia	3,889	5.2 (5.0–5.3)	637	3.0 (2.8–3.3)	177	2.9 (2.4–3.3)	197	3.7 (3.2–4.2)	41	2.4 (1.7–3.3)	65	2.9 (2.2–3.7)	48	2.7 (2.0–3.6)	49	2.2 (1.6–3.0)	28	3.4 (2.2–5.0)	18	3.4 (1.9–5.6)
All-Sites-Combined[c]	105,321	140.6 (139.7–141.5)	20,118	92.4 (91.1–93.7)	5,813	91.4 (89–93.8)	5,260	92.8 (90.3–95.4)	1,053	65.9 (61.8–70.2)	1,729	77.3 (73.6–81.1)	1,797	95.1 (90.7–99.7)	2,373	95.1 (90.9–99.4)	881	112.5 (104.8–120.5)	807	177.3 (164.4–190.9)

Abbreviations: NHL, non-Hodgkin lymphoma; NHW, non-Hispanic White; AANHPI, Asian American/Native Hawaiian/Pacific Islander; NHOPI, Native Hawaiian and Other Pacific Islander

a. Age-adjusted to the 2000 U.S. Standard Population;

b. Includes all groups, not only those detailed here;

c. All-sites-combined includes those listed as well as all others not detailed.

≠ Not reported; rate calculated from observations fewer than 13

Table 4.

Mortality Rate Ratios[a] (MRR) for selected cancers for Non-Hispanic White, AANHPI, and detailed AANHPI race groups. California, 2012–2017.

	NHW	AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
Male	**Referent**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**
Oral Cavity & Pharynx	1	0.78	(0.68–0.89)	1.07	(0.84–1.36)	0.60	(0.45–0.80)	0.60	(0.43–0.86)	0.82	(0.60–1.11)	0.40	(0.25–0.62)	0.61	(0.42–0.89)	1.62	(1.12–2.34)	1.46	(0.94–2.28)
Nasopharynx only	1	5.38	(4.45–6.51)	9.74	(7.81–12.15)	3.69	(2.63–5.19)	≠	≠	5.93	(4.14–8.49)	≠	≠	≠	≠	16.01	(10.80–23.75)	≠	≠
Esophageal	1	0.38	(0.35–0.42)	0.30	(0.25–0.36)	0.37	(0.30–0.45)	0.36	(0.27–0.48)	0.34	(0.26–0.45)	0.39	(0.28–0.53)	0.70	(0.55–0.89)	0.42	(0.26–0.68)	0.80	(0.52–1.23)
Stomach	1	1.91	(1.77–2.07)	2.10	(1.88–2.34)	1.05	(0.87–1.25)	0.48	(0.33–0.70)	1.71	(1.41–2.06)	4.40	(3.82–5.07)	3.05	(2.59–3.59)	1.64	(1.14–2.35)	1.80	(1.18–2.74)
Colorectal	1	0.87	(0.83–0.91)	0.86	(0.8–0.93)	0.89	(0.81–0.98)	0.40	(0.32–0.49)	0.79	(0.69–0.90)	1.18	(1.04–1.34)	0.88	(0.76–1.01)	1.46	(1.21–1.76)	1.39	(1.10–1.75)
Liver	1	2.01	(1.68–2.40)	1.90	(1.55–2.32)	1.55	(1.26–1.91)	0.73	(0.56–0.96)	3.28	(2.68–4.00)	2.71	(2.18–3.37)	0.86	(0.65–1.13)	4.37	(3.44–5.54)	2.05	(1.51–2.80)
Pancreas	1	0.69	(0.65–0.73)	0.73	(0.66–0.80)	0.67	(0.60–0.75)	0.38	(0.30–0.47)	0.49	(0.41–0.59)	0.97	(0.84–1.13)	0.93	(0.80–1.08)	0.75	(0.57–0.99)	0.82	(0.59–1.13)
Lung	1	0.82	(0.79–0.86)	0.87	(0.76–1.00)	0.97	(0.85–1.11)	0.32	(0.27–0.39)	1.10	(0.95–1.28)	0.93	(0.80–1.08)	0.72	(0.61–0.85)	1.27	(1.06–1.51)	1.25	(1.02–1.52)
Prostate	1	0.43	(0.39–0.47)	0.31	(0.26–0.36)	0.68	(0.59–0.78)	0.43	(0.35–0.53)	0.21	(0.17–0.28)	0.28	(0.22–0.36)	0.49	(0.40–0.60)	0.48	(0.35–0.67)	0.94	(0.71–1.25)
Kidney	1	0.61	(0.55–0.67)	0.46	(0.38–0.55)	0.84	(0.72–0.99)	0.49	(0.36–0.67)	0.48	(0.36–0.64)	0.83	(0.64–1.07)	0.79	(0.61–1.02)	≠	≠	≠	≠
Bladder	1	0.35	(0.32–0.39)	0.32	(0.27–0.38)	0.33	(0.27–0.41)	0.30	(0.21–0.42)	0.23	(0.16–0.32)	0.57	(0.44–0.73)	0.53	(0.42–0.67)	≠	≠	≠	≠
Brain	1	0.40	(0.36–0.44)	0.38	(0.32–0.46)	0.43	(0.35–0.52)	0.38	(0.28–0.51)	0.39	(0.30–0.52)	0.43	(0.32–0.59)	0.39	(0.28–0.55)	0.42	(0.25–0.68)	0.58	(0.35–0.97)
NHL	1	0.72	(0.67–0.77)	0.67	(0.59–0.76)	0.86	(0.74–0.99)	0.53	(0.41–0.69)	0.63	(0.50–0.78)	0.56	(0.43–0.74)	0.95	(0.78–1.16)	1.19	(0.87–1.61)	0.74	(0.46–1.19)
Leukemia	1	0.55	(0.50–0.60)	0.47	(0.41–0.55)	0.76	(0.65–0.88)	0.44	(0.34–0.58)	0.61	(0.49–0.75)	0.36	(0.27–0.50)	0.45	(0.34–0.59)	0.62	(0.42–0.93)	0.85	(0.56–1.29)
All-Sites-Combined[c]	1	0.70	(0.69–0.72)	0.71	(0.63–0.79)	0.77	(0.69–0.86)	0.41	(0.36–0.46)	0.80	(0.71–0.89)	0.85	(0.76–0.95)	0.69	(0.61–0.78)	1.09	(0.96–1.23)	1.07	(0.93–1.22)
Female																			

	NHW	AANHPI[b]		Chinese		Filipino		South Asian		Vietnamese		Korean		Japanese		Southeast Asian		NHOPI	
Male	**Referent**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**	**MRR**	**95% CI**
Oral Cavity & Pharynx	1	0.76	(0.66–0.87)	0.89	(0.72–1.11)	0.77	(0.60–0.98)	0.54	(0.31–0.93)	0.69	(0.46–1.03)	0.41	(0.23–0.72)	0.56	(0.36–0.86)	2.05	(1.36–3.07)	0.91	(0.41–2.03)
Nasopharynx only	1	4.96	(3.58–6.86)	9.47	(6.51–13.80)	4.32	(2.62–7.12)	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠	≠
Esophageal	1	0.40	(0.33–0.47)	0.40	(0.29–0.55)	0.20	(0.13–0.32)	0.90	(0.59–1.39)	≠	≠	≠	≠	0.85	(0.60–1.20)	≠	≠	≠	≠
Stomach	1	2.63	(2.42–2.87)	3.04	(2.69–3.43)	1.27	(1.05–1.53)	1.01	(0.69–1.49)	2.41	(1.94–2.99)	5.22	(4.44–6.14)	3.38	(2.84–4.02)	3.30	(2.42–4.51)	4.81	(3.4–6.79)
Colorectal	1	0.78	(0.74–0.82)	0.77	(0.71–0.84)	0.69	(0.63–0.76)	0.39	(0.31–0.50)	0.74	(0.64–0.86)	0.95	(0.82–1.09)	0.92	(0.82–1.04)	1.33	(1.10–1.60)	1.47	(1.16–1.86)
Liver	1	1.59	(1.47–1.72)	1.35	(1.09–1.67)	1.36	(1.09–1.69)	0.78	(0.55–1.10)	2.08	(1.64–2.63)	2.16	(1.69–2.75)	1.37	(1.06–1.79)	3.16	(2.38–4.19)	1.78	(1.18–2.70)
Pancreas	1	0.77	(0.73–0.82)	0.75	(0.69–0.83)	0.76	(0.69–0.84)	0.45	(0.35–0.58)	0.55	(0.46–0.66)	1.09	(0.94–1.25)	1.07	(0.94–1.21)	0.90	(0.70–1.15)	1.08	(0.80–1.46)
Lung	1	0.58	(0.52–0.66)	0.69	(0.61–0.79)	0.50	(0.43–0.57)	0.21	(0.17–0.26)	0.54	(0.46–0.63)	0.48	(0.40–0.56)	0.59	(0.51–0.68)	0.70	(0.58–0.85)	1.15	(0.94–1.40)
Breast	1	0.59	(0.53–0.66)	0.51	(0.44–0.59)	0.73	(0.63–0.84)	0.52	(0.43–0.63)	0.39	(0.32–0.47)	0.43	(0.35–0.52)	0.62	(0.52–0.73)	0.46	(0.35–0.59)	1.33	(1.08–1.65)
Cervix	1	2.35	(1.47–3.76)	1.34	(0.86–2.09)	2.23	(1.45–3.42)	0.87	(0.46–1.63)	1.65	(1.00–2.72)	1.75	(1.04–2.92)	1.53	(0.90–2.62)	5.07	(3.10–8.31)	7.12	(4.28–11.85)
Endometrium	1	0.73	(0.67–0.80)	0.68	(0.56–0.84)	0.99	(0.82–1.20)	0.61	(0.45–0.84)	0.37	(0.27–0.52)	0.51	(0.37–0.70)	0.57	(0.43–0.77)	0.57	(0.37–0.90)	3.34	(2.53–4.42)
Ovary	1	0.78	(0.59–1.03)	0.65	(0.48–0.88)	0.78	(0.58–1.06)	0.80	(0.57–1.13)	0.59	(0.42–0.84)	0.73	(0.52–1.02)	0.71	(0.50–1.00)	0.68	(0.45–1.05)	0.93	(0.59–1.46)
Kidney	1	0.58	(0.51–0.66)	0.66	(0.53–0.82)	0.59	(0.47–0.75)	0.65	(0.43–1.00)	≠	≠	0.62	(0.42–0.92)	0.48	(0.32–0.71)	≠	≠	≠	≠
Bladder	1	0.38	(0.33–0.44)	0.45	(0.35–0.57)	0.21	(0.14–0.30)	≠	≠	0.31	(0.19–0.52)	0.52	(0.34–0.79)	0.60	(0.44–0.82)	≠	≠	≠	≠
Brain	1	0.42	(0.38–0.47)	0.38	(0.32–0.47)	0.42	(0.35–0.52)	0.61	(0.45–0.82)	0.56	(0.43–0.73)	0.30	(0.20–0.44)	0.32	(0.22–0.47)	0.50	(0.31–0.81)	0.71	(0.42–1.21)
NHL	1	0.73	(0.67–0.79)	0.73	(0.63–0.84)	0.85	(0.74–0.98)	0.59	(0.43–0.82)	0.47	(0.35–0.64)	0.49	(0.36–0.67)	0.83	(0.68–1.01)	0.81	(0.55–1.21)	1.33	(0.88–2.03)
Leukemia	1	0.57	(0.52–0.64)	0.54	(0.47–0.63)	0.68	(0.58–0.78)	0.51	(0.37–0.71)	0.59	(0.46–0.76)	0.48	(0.36–0.65)	0.37	(0.28–0.50)	0.68	(0.46–1.02)	0.73	(0.43–1.24)
All-Sites-Combined[c]	1	0.69	(0.65–0.74)	0.68	(0.61–0.75)	0.72	(0.65–0.80)	0.48	(0.43–0.54)	0.59	(0.53–0.66)	0.70	(0.63–0.78)	0.69	(0.62–0.77)	0.89	(0.79–1.01)	1.41	(1.25–1.58)

Abbreviations: NHL, non-Hodgkin lymphoma; NHW, non-Hispanic White; AANHPI, Asian American/Native Hawaiian/Pacific Islander; NHOPI, Native Hawaiian and Other Pacific Islander

[a] MRRs derived from negative binomial regression;

[b] Includes all groups, not only those detailed here;

[c] All-sites-combined includes those listed as well as all others not detailed.

[‡] Not reported; observations fewer than 13

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2022 January 01.

Table 5.

Summary of key findings: cancer mortality patterns for AANHPI groups in relation to NHW. California, 2012–2017.

• NHOPIs have higher mortality for stomach, colorectal, liver, lung (males), breast, cervix, and endometrium cancer
• Southeast Asians have higher mortality for oral cavity and pharynx, nasopharynx (males), stomach, colorectal, liver, lung (males), and cervix cancer
• Vietnamese have higher mortality for nasopharynx (males), stomach, liver, and cervix cancer
• Koreans have higher mortality for stomach, colorectal (males), liver, and cervix cancer
• Chinese have higher mortality for nasopharynx, stomach, and liver cancer
• Filipinos have higher mortality for nasopharynx, liver, stomach (females), and cervix cancer
• Japanese have higher mortality for stomach and liver (females) cancer
• South Asians have a unique cancer mortality profile among AANHPIs, with the lowest mortality for all cancer sites combined, and significantly lower lung, colorectal, and pancreatic cancer mortality; for infection-related cancers (cervix-females, stomach, liver) which are typically high among AANHPIs, rates are significantly lower among South Asian males and equivalent between NHW and South Asian females

Abbreviations: NHW, non-Hispanic White; AANHPI, Asian American/Native Hawaiian/Pacific Islander; NHOPI, Native Hawaiian and Other Pacific Islander